The present invention provides a method of treating squamous histology cancers and PI3K pathway activated large cell lung and colorectal cancers in a patient comprising administering to a patient in need of such treatment an effective amount of 8-[5-(1-hydroxy-1-methylethyl)pyridin-3-yl]-1-[(2S)-2-methoxypropyl]-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one, or a pharmaceutically acceptable salt thereof in combination with an effective amount of necitumumab.本發明提供治療患者之鱗狀組織學癌症及PI3K路徑活化大細胞肺及結腸直腸癌症之方法,其包含投與需要此類治療之患者有效量之8-[5-(1-羥基-1-甲基乙基)吡啶-3-基]-1-[(2S)-2-甲氧基丙基]-3-甲基-1,3-二氫-2H-咪唑并[4,5-c]喹啉-2-酮或其醫藥學上可接受之鹽與有效量之耐昔妥珠單抗(necitumumab)之組合。